Back to discover
Drug

Brentuximab vedotin

Approved medicine
ResearchOngoing research

Also known as Adcetris, Brentuximab vedotin brentuximab, Brentuximab vedotina, Moab, chimeric, SGN-30, to CD30 antigen.

RxNorm1147320UNII7XL5ISS668
1
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Brentuximab vedotin
Aliases & brands
AdcetrisBrentuximab vedotin brentuximabBrentuximab vedotinaMoab, chimeric, SGN-30, to CD30 antigen
RxNorm CUI
1147320
UNII
7XL5ISS668

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes2
Epstein-Barr Virus Infections1Immunoconjugates1
Journals, researchers & institutions
Top journals
  • Molecular cancer therapeutics1
Leading researchers
  • Anderson ME1
  • Cao AT1
  • Gardai SJ1
  • Heiser RA1
  • Jonas M1
  • Law CL1
  • Thurman R1
  • Trueblood ES1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature